Regulatory FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares BioPharma DiveIndustry executives can share their views on the national priority program at a June meeting.RegulatoryRead full story pharminent March 24, 2026 BioPharma Dive Industry executives can share their views on the national priority program at a June meeting. Regulatory Read full story Post navigation Previous: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit ManagersNext: Immutrin raises $87M to advance drug for progressive heart disease Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
